SciSparc Ltd. (SPRC)
NASDAQ: SPRC · Real-Time Price · USD
0.223
-0.010 (-4.20%)
At close: Nov 4, 2024, 4:00 PM
0.229
+0.005 (2.33%)
After-hours: Nov 4, 2024, 5:53 PM EST
SciSparc Revenue
In the year 2023, SciSparc had annual revenue of $2.88M with 113.73% growth. SciSparc had revenue of $907.00K in the half year ending December 31, 2023.
Revenue (ttm)
$2.88M
Revenue Growth
+113.73%
P/S Ratio
0.03
Revenue / Employee
$959,667
Employees
3
Market Cap
726.33K
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
LogicMark | 9.74M |
Elevai Labs | 2.47M |
Catheter Precision | 436.00K |
Aditxt | 329.74K |
Cyclacel Pharmaceuticals | 80.00K |
SPRC News
- 5 weeks ago - SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment - GlobeNewsWire
- 5 weeks ago - SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX - GlobeNewsWire
- 6 weeks ago - SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment - GlobeNewsWire
- 6 weeks ago - SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment - GlobeNewsWire
- 7 weeks ago - SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy - GlobeNewsWire
- 7 weeks ago - SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax's Direct Import Agreement with Major Chinese Vehicle Manufacturer - GlobeNewsWire
- 2 months ago - SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment - GlobeNewsWire
- 2 months ago - SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination - GlobeNewsWire